Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Capobianco

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Journal of Neuroinflammation|October 30, 2016
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeSven Jarius, Klemens Ruprecht, Ingo Kleiter, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Multiple Sclerosis and Related Disorders|June 8, 2022
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple SclerosisMarta Ponzano, Irene Schiavetti, Francesca Bovis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
European Journal of Neurology|September 24, 2021
A real-world study of alemtuzumab in a cohort of Italian patientsCinzia Valeria Russo, Francesco Saccà, Jessica Frau, et al.
Journal of Neuroinflammation|January 21, 2022
Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patientsSven Jarius, Florence Pache, Peter Körtvelyessy, et al.
The Lancet. Neurology|August 21, 2021
Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Yael Hacohen, Alvaro Cobo-Calvo, et al.
Journal of Neurology|February 22, 2021
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Pietro Annovazzi, Paolo Ragonese, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 19, 2025
Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and DiscrepanciesSara Carta, Elia Sechi, Alessandro Dinoto, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Journal of Neuroinflammation|October 30, 2016
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeSven Jarius, Klemens Ruprecht, Ingo Kleiter, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Multiple Sclerosis and Related Disorders|June 8, 2022
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple SclerosisMarta Ponzano, Irene Schiavetti, Francesca Bovis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
European Journal of Neurology|September 24, 2021
A real-world study of alemtuzumab in a cohort of Italian patientsCinzia Valeria Russo, Francesco Saccà, Jessica Frau, et al.
Journal of Neuroinflammation|January 21, 2022
Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patientsSven Jarius, Florence Pache, Peter Körtvelyessy, et al.
The Lancet. Neurology|August 21, 2021
Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Yael Hacohen, Alvaro Cobo-Calvo, et al.
Journal of Neurology|February 22, 2021
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Pietro Annovazzi, Paolo Ragonese, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 19, 2025
Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and DiscrepanciesSara Carta, Elia Sechi, Alessandro Dinoto, et al.
Pageof 8